SBH
TPTX

Segall Bryant & Hamill’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Segall Bryant & Hamill’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-130,011
Closed -$9.78M – 756
2022
Q2 		$9.78M Buy
130,011
+38,680
+42% +$1.72M 0.11% 206
2022
Q1 		$2.45M Buy
91,331
+211
+0.2% +$7.09K 0.02% 416
2021
Q4 		$4.35M Buy
91,120
+38,145
+72% +$1.71M 0.04% 337
2021
Q3 		$3.52M Buy
52,975
+1,212
+2% +$86.3K 0.03% 390
2021
Q2 		$4.04M Buy
51,763
+2,824
+6% +$209K 0.04% 365
2021
Q1 		$4.63M Sell
48,939
-497
-1% -$59.1K 0.05% 349
2020
Q4 		$6.02M Sell
49,436
-907
-2% -$99.4K 0.07% 263
2020
Q3 		$4.4M Buy
50,343
+36,379
+261% +$2.53M 0.06% 279
2020
Q2 		$903K Buy
13,964
+3,741
+37% +$216K 0.02% 463
2020
Q1 		$457K Buy
10,223
+3,508
+52% +$186K 0.01% 611
2019
Q4 		$419K Buy
+6,715
New +$320K 0.01% 685

Segall Bryant & Hamill's TPTX Position: Q3 2022 in Review

Segall Bryant & Hamill sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 130,011 shares — an estimated $9.78M sold.

Segall Bryant & Hamill first reported a position in TPTX in Q4 2019 and held it in 11 quarters. The position peaked at $9.78M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

  • Segall Bryant & Hamill reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Segall Bryant & Hamill sold 130,011 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $9.78M.
  • Segall Bryant & Hamill first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • Segall Bryant & Hamill's Turning Point Therapeutics, Inc. Common Stock position peaked at $9.78M in Q2 2022.
  • 0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Segall Bryant & Hamill's 13F filing for Q3 2022, filed 14 Nov 2022.